rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CRDF
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Cardiff Oncology at UBS conference: phase iii push gains speed
      Nov 16Investing.comCRDFUBS
      Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update
      Nov 12Yahoo FinanceCRDF
      Cardiff Oncology to Participate in the UBS Global Biopharma Conference
      Nov 3Yahoo FinanceCRDF
      Cardiff Oncology names Leila Alland interim chief medical officer
      Oct 27Investing.comCRDF
      Cardiff Oncology Appoints Leila Alland, MD, as Interim Chief Medical Officer
      Oct 27Yahoo FinanceCRDF
      FDA grants orphan drug status to Cardiff’s onvansertib for CMML
      Oct 21Investing.comCRDF
      Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia
      Oct 21Yahoo FinanceCRDF
      Taiho Oncology and Taiho Pharmaceutical Announce Positive Topline Results in Phase 3 AZTOUND Trial Evaluating Oral Azacitidine and Cedazuridine in Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
      Sep 30Yahoo FinanceCRDF
      Analysts Conflicted on These Healthcare Names: High Tide (HITI), Cardiff Oncology (CRDF) and Benitec Biopharma (BNTC)

      Detailed price information for Benitec Biopharma Ltd ADR (BNTC-Q) from The Globe and Mail including charting and trades.

      Sep 16The Globe and MailBNTCCRDF
      HC Wainwright Upgrades Cardiff Oncology to Buy From Neutral, Price Target is $9

      Cardiff Oncology (CRDF) has an average rating of hold and mean price target of $4.17, according to a

      Sep 15Yahoo FinanceCRDF
      Cardiff Oncology Shares Rise After Upgrade From HC Wainwright
      Sep 15Yahoo FinanceCRDF
      Cardiff Oncology at H.C. Wainwright conference: trial path clears
      Sep 14Investing.comCRDF
      Cardiff Oncology settles dispute with NMS over onvansertib rights
      Sep 14Investing.comCRDF
      Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement

      Under the terms of the Amendment, all disputed issues are resolvedSAN DIEGO and NERVIANO, Italy, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ: CRDF) ("Cardiff") and Nerviano Medical Sciences S.r.l. ("NMS") today announced that they have reached a settlement and amended their 2017 Exclusive License Agreement, resolving all outstanding disputes between the two companies related to the global rights for onvansertib, Cardiff's lead PLK1 inhibitor drug candidate, and establishing

      Sep 14Yahoo FinanceCRDF
      Cardiff Oncology, Inc. (CRDF) Presents at 8th Annual RAS-Targeted Drug Development Summit - Slideshow (NASDAQ:CRDF) 2026-09-10

      2026-09-10. The following slide deck was published by Cardiff Oncology, Inc.

      Sep 10Seeking AlphaCRDF
      Cardiff Oncology, Inc. (CRDF) Presents at 8th Annual RAS-Targeted Drug Development Summit - Slideshow
      Sep 10Seeking AlphaCRDF
      Cardiff Oncology to Participate in September 2026 Conferences

      SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that Mani Mohindru, Ph.D. will participate in two upcoming conferences. Details of the company’s participation are as follows: 8th Annual RAS-Targeted Drug Development Summit Advancing PLK1 Targeted Therapy to Transform Outcomes in RAS Mutant Metastatic Colorectal Cancer; Tuesda

      Sep 2Yahoo FinanceCRDF

      This is the newest page. Registered accounts read further back.